114177-14-9 Usage
Description
Milbemycin A3 oxime is an anthelmintic, a derivative of milbemycin A3 , and a component of milbemycin oxide . It reduces the number of microfilariae of the heartworm D. immitis in the blood of naturally infested dogs by 85.2% when administered at a dose of 0.05 mg/kg. Formulations containing milbemycin A3 oxime, in combination with milbemycin A4 oxime, have been used in the treatment of parasitic infections in dogs.
Uses
Different sources of media describe the Uses of 114177-14-9 differently. You can refer to the following data:
1. Milbemycin A3 oxime is a semi-synthetic macrocyclic lactone prepared by the oxidation and oximation of a mixture of milbemycin A3. Milbemycin A3 oxime is the minor component (~30%) in the commercial product milbemycin oxime, marketed for endo- and exo-parasite infections. Like the other milbemycin/avermectins, milbemycin A3 oxime acts by opening glutamate sensitive chloride channels in neurons of invertebrates leading to paralysis by hyperpolarisation of these cells and signal transfer blocking.
2. Milbemycin A3 oxime is the minor component of the anti-parasitic product milbemycin oxime.
Check Digit Verification of cas no
The CAS Registry Mumber 114177-14-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,1,4,1,7 and 7 respectively; the second part has 2 digits, 1 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 114177-14:
(8*1)+(7*1)+(6*4)+(5*1)+(4*7)+(3*7)+(2*1)+(1*4)=99
99 % 10 = 9
So 114177-14-9 is a valid CAS Registry Number.
114177-14-9Relevant articles and documents
METHOD FOR SYNTHESIZING MILBEMYCIN OXIME
-
Paragraph 0022-0033, (2017/04/14)
The present invention provides a method for synthesizing Milbemycin oxime. The method comprises the following steps. (1) Oxidizing reaction: oxidizing Milbemycin, using hypochlorite or chlorite as oxidizers and piperidine nitrogen oxygen free radicals as the catalyst and halide as the catalyst promoter. The oxidation reaction is conducted in a dichloromethane solvent for 0.5-4 hours at ?5-15° C. to produce the intermediate product Milbemycin ketone. (2) Oximation reaction: reacting the Milbemycin ketone with a hydroxylamine hydrochloride oximation agent in a 1,4-dioxane reaction solvent for 10-16 hours at 25-35° C. to obtain Milbemycin oxime. The method provided by the present invention realized the industrial production of Milbemycin oxime for the first time domestically. Moreover, the yield of the prepared product is higher than competing products both at home and abroad.
